I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

HSG 2022

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Nov 3 / Roche and Genentech
Relationship between biomarkers and clinical signs and symptoms in adult manifest Huntington’s disease: A cross-sectional analysis from baseline GENERATION HD1
Identifying sensitive biomarkers of pathology in Huntington’s disease (HD), that relate to clinical signs and symptoms, is important for the development of disease-modifying therapies in HD. This poster describes the assessment of the relationship between imaging/fluid biomarkers and clinical/digital endpoints in manifest HD, using data from GENERATION HD1 (NCT03761849).

Sign up or login to unlock the full suite of MEDICALLY features

Nov 3 / Roche and Genentech
Describing the safety profile of tominersen using integrated data from across the tominersen clinical development programme
This poster describes the safety profile of tominersen at different dosing regimens using data from across the tominersen programme. The adverse event profiles, including lumbar puncture-related events, of different dosing frequencies of intrathecal 120 mg tominersen (every 4, 8 or 16 weeks) compared with placebo, are assessed.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 3 / Roche and Genentech
GENERATION HD2, a Phase II dose-finding study of tominersen
GENERATION HD2 is a new Phase II study to evaluate the safety, biomarker response and efficacy of tominersen. This presentation outlines the objectives and study design of GENERATION HD2, as well as highlighting Roche’s continued commitment to HD research, through the exploration of other therapeutic approaches and collaborations with the community.
04:00 PM
Duration 15mins Main Ballroom
GENERATION HD2, a Phase II dose-finding study of tominersen
Peter McColgan

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar